SCHEMBL6523529

SCHEMBL6523529

Cc1c(-c2ccccc2)nc2ccc(-c3ccc(F)c(C(O[SiH](C)C)C(C)(C)C)c3F)cn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MAPT P10636 1/20 0.37
TOP2A P11388 1/20 0.36
SLC2A1 P11166 4/20 0.34
CYP11B1 P15538 4/20 0.33
CYP11B2 P19099 4/20 0.33
SLC2A2 P11168 1/20 0.33
ADRA1B P35368 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NR1H4 Q96RI1 2/20 0.31
ALDH1A1 P00352 2/20 0.31
TGFBR1 P36897 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3435401 0.87 NR1H4 (0.34) KDM4EMAPTSLC2A1NR1H4ALDH1A1
SCHEMBL2064144 0.76 NR4A2 (0.40)
SCHEMBL6520517 0.74 MAPK14 (0.37) SLC2A1CYP11B1CYP11B2
SCHEMBL2063438 0.74 NR4A2 (0.42) KDM4ENPC1RAB9AMAPTCYP11B1
SCHEMBL6519571 0.73 NR4A2 (0.50) KDM4ENPC1RAB9AMAPTTOP2A
SCHEMBL6523534 0.73 SLC2A1 (0.39) KDM4ENPC1RAB9AMAPTTOP2A
SCHEMBL2064753 0.69 FEN1 (0.41)
SCHEMBL2064626 0.66 ABL1 (0.40)
SCHEMBL3427898 0.66 NR1H4 (0.39) KDM4EMAPTSLC2A1NR1H4ALDH1A1
SCHEMBL6524183 0.66 DHODH (0.44) KDM4ENPC1RAB9AMAPTSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN KDM4E 2017/4885NPC1 996/4885RAB9A 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.